secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALPINE IMMUNE SCIENCES, INC. (—)
CIK:        0001626199
Form:       8-K
Filed at:   2024-05-20T23:59:59+00:00
Accession:  0001193125-24-142285
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 5.01, 5.03, 3.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex completes $5B acquisition of Alpine Immune Sciences at $65/share, Alpine to be delisted
--------------------------------------------------------------------------------

- Approximately 87% of shares tendered; Merger Sub accepted all validly tendered shares on May 18, closed May 20.
- Each Alpine share converted to $65 cash; total equity value of ~$5B funded by Vertex's cash on hand.
- Alpine terminated ESPP, stock plans, and at-the-market sales agreement with Cowen, effective May 30.
- All prior directors and officers removed; Charles Wagner appointed as sole director; Reshma Kewalramani, Wagner, and Jonathan Biller as officers.
- Nasdaq trading halted May 17; delisting and deregistration of shares under Section 12(b) initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626199/000119312524142285/0001193125-24-142285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626199/000119312524142285/d842347d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-142285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer